World Health Organization. (2019). International Statistical Classification of Diseases and Related Health Problems, 10th Revision (ICD-10). Geneva: WHO.
[2]
American Urological Association. (2021). Guideline on Management of Benign Prostatic Hyperplasia (BPH). Linthicum, MD: AUA.
[3]
Carter, H.B., et al. (2020). Early detection of prostate cancer: AUA Guideline. Journal of Urology, 204(4), 683-690.
[4]
European Association of Urology. (2022). Guidelines on Prostate Cancer. Arnhem: EAU.
[5]
Nickel, J.C., et al. (2019). The prevalence of prostatitis: A population-based study. European Urology, 76(4), 442-449.
[6]
Krupski, T.L., et al. (2021). Evaluation and treatment of prostate disorders. Primary Care: Clinics in Office Practice, 48(2), 245-260.
[7]
Mayo Clinic. (2022). Prostate Health: Diseases and Conditions. Rochester, MN: Mayo Foundation for Medical Education and Research.
[8]
National Institute of Diabetes and Digestive and Kidney Diseases. (2021). Prostate Enlargement (Benign Prostatic Hyperplasia). Bethesda, MD: NIDDK.
[9]
McNeal, J.E. (2018). Normal anatomy of the prostate and changes in benign prostatic hyperplasia. The Prostate, 78(S2), S3-S12.
[10]
Roehrborn, C.G. (2020). Male lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). Medical Clinics, 104(3), 407-424.